Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070171 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL9067361 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385198 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385408 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29386171 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5173973 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29385929 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL10791516 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL7746290 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5173963 | 0.92 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RES MUNICH GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20250163179-A1 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-12281172-B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| US-11987633-B2 | Cross-species-specific single domain bispecific single chain antibody | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20230357444-A1 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN | AMGEN RES MUNICH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-4180458-A1 | CROSS-SPECIES-SPECIFIC PSMA X CD3 BISPECIFIC SINGLE CHAIN ANTIBODY | Amgen Research (Munich) GmbH (DE) | 2023-05-17 | — | — | EP | disclosed |
| US-20230037742-A1 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-2155783-B2 | CROSS-SPECIES-SPECIFIC CD3-EPSILON BINDING DOMAIN | AMGEN RES MUNICH GMBH (DE) | 2022-10-19 | — | — | EP | disclosed |
| US-11472886-B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2022-10-18 | — | — | US | disclosed |
| EP-4059964-A1 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN | Amgen Research (Munich) GmbH (DE) | 2022-09-21 | — | — | EP | disclosed |
| JP-2022137063-A | PEGYLATED PORCINE INTERFERON AND METHOD OF USE THEREOF | エランコ・ユーエス・インコーポレイテッド | 2022-09-21 | — | — | JP | disclosed |
| US-20220041736-A1 | CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| JP-2000016949-A | THERAPEUTIC OR PROPHYLACTIC AGENT OF STOMATITIS, MUCOUS MEMBRANE DAMAGE OF DIGESTIVE TRACT OR CUTANEOUS ULCER | NIPPON KAYAKU CO LTD | 2000-01-18 | — | — | JP | disclosed |
| US-5736523-A | ADMINISTERING TO THE MAMMAL SUFFERING FROM CANCER | BIOCHEM PHARMA INC. (CA) | 1998-04-07 | — | — | US | disclosed |
| US-5606037-A | Processes antineoplastic heteronaphthoquinones | BIOCHEM PHARMA INC. (CA) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | MET, IGF1R, INHA | ALDH1A1 1470/4885MAPT 3876/4885LMNA 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.